Diary - News All news Imaxio receives scientific advice from the European Medicines Agency

Imaxio receives scientific advice from the European Medicines Agency

Imaxio receives scientific advice from the European Medicines Agency (EMA) for its influenza vaccine candidate IMX836

Imaxio plans to make IMX836 reach the clinic by early 2018

Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans.

This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836.

Read the press release

Headlines

Our members

Orphelia Pharma : CHMP has adopted a positive opinion for Ivozall

October 1^st, 2019

THERANEXUS ANNOUNCES INCLUSION OF LAST SUBJECT IN ITS PHASE IB TRIAL OF THN201

September 17^th, 2019

Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL065

September 17^th, 2019

All news

Contact

Bâtiment Domilyon - 321, avenue Jean Jaurès - 69007 Lyon

Tel. : 04.72.76.53.30 - Fax : 09.55.91.30.26

info@lyonbiopole.com

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree